SCYNEXIS SCYX 深 沪
已收盘 12-12 16:00:00 美东时间
0.6459
+0.001
+0.17%
华盛通- 最 高0.6549
- 今 开0.65
- 成交量 28.42万股
- 最 低 0.6346
- 昨 收 0.6448
- 总市值 2520.32万
- 52周最高 1.49
- 市盈率 静 --
- 换手率 0.73%
- 52周最低 0.565
- 委 比 -99.55%
- 总股本 3902.03万
- 历史最高 150.00
- 量 比 1.11
- 振 幅 3.15%
- 历史最低 0.565
- 每 手 1
- 风险率 0.18%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Trevi Therapeutics appoints new CFO
Trevi Therapeutics (TRVI) named David Hastings as its next chief financial officer, effective January 6, 2026. Hastings prior roles include CFO positions at Arbutus, Unilife, and Incyte. Hastings curr...
12-04 20:43
Trevi Therapeutics Appoints Veteran Finance Leader David Hastings as New CFO Starting January 2026
Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with
12-04 20:33
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Shuttle Pharmaceuticals (NASDAQ:SHPH) stock increased by 18.6% to $2.1...
11-21 05:06
SCYNEXIS Completes Transfer Of BREXAFEMME New Drug Application To GSK
GSK remains committed to the relaunch of BREXAFEMME, and following its relaunch, SCYNEXIS stands to receive up to $145.5 million in annual net sales milestones as well as royalties, net of payments to Merck, in the low
11-19 20:09
SCYNEXIS Secures 5-Year $7M Annual Federal Grant To Advance Next-Generation Antifungal Therapies
Five-year grant of $7 million annually to the academic researchers is aimed at accelerating the development of new therapeutics to combat resistant fungal infections, including the Company's next generation of
11-17 23:17
SCYNEXIS Q3 EPS $(0.17) Beats $(0.20) Estimate, Sales $334.000K Beat $147.667K Estimate
SCYNEXIS (NASDAQ:SCYX) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.20) by 15 percent. This is a 183.33 percent decrease over losses of $(0.06) per share from the same
11-06 06:04
SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update
SCYNEXIS announced Q3 2025 financial results, highlighting a $24.8 million one-time payment from GSK to resolve the Phase 3 MARIO study disagreement. The company also shared positive SAD/MAD data for its second-generation antifungal, SCY-247, expecting to begin Phase 2 studies in 2026. GSK continues to support the relaunch of BREXAFEMME, with potential milestones and royalties for SCYNEXIS. The company ended Q3 with $37.9 million in cash, which w...
11-05 21:20
美股大行评级 | 上调！苹果、亚马逊、Amkor Tech、Cadence、Confluent、卡特、通用动力等获多家上调目标价
今日重点评级关注：HC Wainwright & Co.：维持PepGen"买入"评级，目标价从12美元升至18美元；Piper Sandler：维持Prothena Corp"超配"评级，目标价从15美元升至36美元
10-29 09:25
Guggenheim Maintains Buy on SCYNEXIS, Lowers Price Target to $3
Guggenheim analyst Vamil Divan maintains SCYNEXIS (NASDAQ:SCYX) with a Buy and lowers the price target from $4 to $3.
10-28 20:41
SCYNEXIS and GSK Amend License Agreement
SCYNEXIS ( ($SCYX) ) has shared an update. On October 14, 2025, SCYNEXIS and GS...
10-15 20:29
